| Robert E Helm Jr, MD | |
|
333 Borthwick Ave, Mob Suite 402, Portsmouth, NH 03801-7128 | |
| (603) 559-4111 | |
| (603) 559-4110 |
| Full Name | Robert E Helm Jr |
|---|---|
| Gender | Male |
| Speciality | Thoracic Surgery |
| Experience | 34 Years |
| Location | 333 Borthwick Ave, Portsmouth, New Hampshire |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831153337 | NPI | - | NPPES |
| 2096650 | Medicaid | MA | |
| 3075027 | Medicaid | NH | |
| E400184900 | Medicaid | ME |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208G00000X | Thoracic Surgery (cardiothoracic Vascular Surgery) | 11021 (New Hampshire) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cornerstone Vna | Rochester, NH | Home health agency |
| Rockingham Vna And Hospice | Exeter, NH | Home health agency |
| Portsmouth Regional Hospital | Portsmouth, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Appledore Medical Group Inc | 5698666154 | 89 |
News Archive
OncoGenex Pharmaceuticals, Inc., today announced that a randomized, controlled, investigator-sponsored Phase 2 clinical trial evaluating OGX-427 when administered as a monotherapy to patients with castrate resistant prostate cancer (CRPC) has received grant funding.
The information encoded in the DNA of an organism is not sufficient to determine the expression pattern of genes. This fact has been known even before the discovery of epigenetics, which refers to external modifications to the DNA that turn genes "on" or "off".
Precision Therapeutics, Inc., a life science company that develops personalized medicine products for individualizing cancer care, today announced that a clinical study which demonstrates the feasibility of the ChemoFx chemoresponse assay to identify patients unlikely to respond to first-line therapy has been accepted for presentation at the 2013 Annual Meeting of the Western Association of Gynecologic Oncologists.
Biogen Idec today issued the following statement regarding the United States (U.S.) Food and Drug Administration (FDA) approval of AMPYRA™ (dalfampridine) to improve walking in patients with multiple sclerosis (MS).
› Verified 7 days ago
| Entity Name | Appledore Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720077167 PECOS PAC ID: 5698666154 Enrollment ID: O20040601000165 |
News Archive
OncoGenex Pharmaceuticals, Inc., today announced that a randomized, controlled, investigator-sponsored Phase 2 clinical trial evaluating OGX-427 when administered as a monotherapy to patients with castrate resistant prostate cancer (CRPC) has received grant funding.
The information encoded in the DNA of an organism is not sufficient to determine the expression pattern of genes. This fact has been known even before the discovery of epigenetics, which refers to external modifications to the DNA that turn genes "on" or "off".
Precision Therapeutics, Inc., a life science company that develops personalized medicine products for individualizing cancer care, today announced that a clinical study which demonstrates the feasibility of the ChemoFx chemoresponse assay to identify patients unlikely to respond to first-line therapy has been accepted for presentation at the 2013 Annual Meeting of the Western Association of Gynecologic Oncologists.
Biogen Idec today issued the following statement regarding the United States (U.S.) Food and Drug Administration (FDA) approval of AMPYRA™ (dalfampridine) to improve walking in patients with multiple sclerosis (MS).
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Robert E Helm Jr, MD 333 Borthwick Ave, Mob Suite 402, Portsmouth, NH 03801-7128 Ph: (603) 559-4111 | Robert E Helm Jr, MD 333 Borthwick Ave, Mob Suite 402, Portsmouth, NH 03801-7128 Ph: (603) 559-4111 |
News Archive
OncoGenex Pharmaceuticals, Inc., today announced that a randomized, controlled, investigator-sponsored Phase 2 clinical trial evaluating OGX-427 when administered as a monotherapy to patients with castrate resistant prostate cancer (CRPC) has received grant funding.
The information encoded in the DNA of an organism is not sufficient to determine the expression pattern of genes. This fact has been known even before the discovery of epigenetics, which refers to external modifications to the DNA that turn genes "on" or "off".
Precision Therapeutics, Inc., a life science company that develops personalized medicine products for individualizing cancer care, today announced that a clinical study which demonstrates the feasibility of the ChemoFx chemoresponse assay to identify patients unlikely to respond to first-line therapy has been accepted for presentation at the 2013 Annual Meeting of the Western Association of Gynecologic Oncologists.
Biogen Idec today issued the following statement regarding the United States (U.S.) Food and Drug Administration (FDA) approval of AMPYRA™ (dalfampridine) to improve walking in patients with multiple sclerosis (MS).
› Verified 7 days ago
Dr. John Anthony Federico, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 333 Borthwick Avenue, Suite 402, Portsmouth, NH 03801 Phone: 603-559-4111 Fax: 406-752-8220 | |
William P Berry, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Not Enrolled in Medicare Practice Location: 333 Borthwick Ave, Suite 402, Portsmouth, NH 03801 Phone: 603-559-4111 Fax: 603-559-4110 | |
Dr. Christopher Terrien Iii, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 333 Bothwick Avenue, Suite 402, Portsmouth, NH 03801 Phone: 603-559-4111 |